Yifei Wang
Department of Pancreatic Cancer,
National Clinical Research Center for Cancer,
Tianjin's Clinical Research Center for Cancer,
Tianjin Key Laboratory of Digestive Cancer,
Key Laboratory of Cancer Prevention and Therapy,
Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy
Tianjin Medical University Cancer Institute and Hospital
Hao Wang is a Professor in College of Life Sciences, South China Agricultural University, Canton, China. He received his bachelor and M. Phil. degree from Lanzhou University in Gansu Province, China, and a Ph.D. from The Chinese University of Hong Kong, Hong Kong.
As a post-doctoral fellow in Johns Hopkins University and The Chinese University of Hong Kong, he focused on characterizing the roles of endomembrane trafficking and protein targeting in cell polarization using pollen tubes as a model system. There he set up and optimized a useful system to transiently express and analyze florescent reporter proteins in plant pollen tubes. By combination of the transient expression system with biochemical, genetic, molecular and advanced bio-imaging approaches, he further studied the roles of protein secretion, exocytosis and endocytosis in regulating cell polarity. Since establishing an independent lab in 2014, Dr. Wang’s research has been focus on studying the unconventional protein secretion and understanding how endomembrane trafficking regulates cell polarity and growth.
Dr. Wang has served as a reviewing editor (plant cell biology) of Frontiers in Plant Science since 2015. The work in Dr. Wang’s laboratory is currently supported by the National Natural Science Foundation of China (NSFC), the Natural Science Foundation of Guangdong Province and Canton, China.
Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma.
Scientific reports Aug, 2015 | Pubmed ID: 26250939
STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Clinical science (London, England : 1979) Mar, 2019 | Pubmed ID: 30782607
Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Jun, 2021 | Pubmed ID: 33712388
PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer.
Cancer letters Sep, 2021 | Pubmed ID: 34052329
High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma.
Thoracic cancer Feb, 2022 | Pubmed ID: 34951127
Serum IL-35 levels is a new candidate biomarker of cancer-related cachexia in stage IV non-small cell lung cancer.
Thoracic cancer Mar, 2022 | Pubmed ID: 35142058
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Cancer letters Nov, 2022 | Pubmed ID: 35981571
MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Journal for immunotherapy of cancer Nov, 2022 | Pubmed ID: 36319063
SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation.
Gut Feb, 2023 | Pubmed ID: 36828627
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Journal of experimental & clinical cancer research : CR May, 2023 | Pubmed ID: 37143164
Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2 Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy.
Gastroenterology Jul, 2024 | Pubmed ID: 38492894
The ATF4-RPS19BP1 axis modulates ribosome biogenesis to promote erythropoiesis.
Blood Aug, 2024 | Pubmed ID: 38657191
CD64 fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8 T cells.
Gut Nov, 2024 | Pubmed ID: 39187291
Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk.
Surgery Nov, 2024 | Pubmed ID: 39191600
Computational modeling of mast cell tryptase family informs selective inhibitor development.
iScience Sep, 2024 | Pubmed ID: 39280611
The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.
Cancer letters Dec, 2024 | Pubmed ID: 39710057
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Xiangqin Zhao1,
Xinbo Gao1,
Wenwen Yu2,
Yi Lu1,
Xuesong Li1,
Lu Tan3,
Xiubao Ren2,
Yifei Wang1,
Weijie Song4,
Jihui Hao1,
Ying Ma1
1Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital,
2Department of Immunology and Biotherapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital,
3Research Core Facility, School of Basic Medical Sciences, Tianjin Medical University,
4Department of Public Laboratory, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved